Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 9/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950024 | 1.00 | HTR1A (0.61) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL823058 | 1.00 | HTR1A (0.61) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL29507805 | 1.00 | HTR1A (0.61) | HTR1ADRD2DRD4DRD3CHRM3 | |
| Hydrochloric Acid SCHEMBL29064497 | 0.98 | HTR1A (0.59) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL29236103 | 0.94 | HTR1A (0.58) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL11636988 | 0.89 | SIGMAR1 (0.56) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL2248107 | 0.84 | DRD3 (0.54) | HTR1ADRD3HTR7 | |
| SCHEMBL31808827 | 0.84 | DRD3 (0.54) | HTR1ADRD3HTR7 | |
| Bromide SCHEMBL29349994 | 0.82 | HTR1A (0.56) | HTR1ADRD2DRD4DRD3CHRM3 | |
| SCHEMBL12125968 | 0.81 | DRD3 (0.65) | HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8053603-B2 | Tetralone-based monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2049090-B1 | USE OF 5-HT7 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | ESTEVE LABOR DR (ES) | 2011-10-05 | — | — | EP | disclosed |
| US-20090326014-A1 | Use of 5-ht7 receptor agonists for the treatment of pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | disclosed |
| EP-2049090-A1 | USE OF 5-HT7 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| EP-1875899-A1 | Use of 5HT7 receptor agonists for the treatment of pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-09 | — | — | EP | disclosed |
| WO-2008000495-A1 | USE OF 5-HT7 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | LABORATORIOS DEL DR. ESTEVE, S.A (ES) | 2008-01-03 | — | — | WO | disclosed |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR1A 13/4885DRD2 409/4885DRD4 883/4885 |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | HTR1A 33/4885DRD2 112/4885DRD4 143/4885 |
| US-20090326014-A1 | Use of 5-ht7 receptor agonists for the treatment of pain | HTR7, HTR1A, OPRL1 | HTR1A 2/4885DRD2 200/4885DRD4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.